Eloxatin with infusional 5-fluorouracil and leucovorin was shown to lower the chance of colon cancer returning when given to patients with stage III colon cancer after surgery to remove the tumor. Eloxatin also increases survival in patients with stage III colon cancer. Eloxatin with infusional 5-fluorouracil and leucovorin was also shown to increase survival, shrink tumors and delay growth of tumors in some patients with advanced colorectal cancer. Eloxatin is in a class of medications called platinum-containing antineoplastic agents. It works by killing cancer cells.

It is not known if Eloxatin works in children.